Skip to content
10-Q

Quarterly Report

SPYRE THERAPEUTICS, INC. SYRE

0001636282-26-000050

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 28, 2026 86.84M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$57.37M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$40.99M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $97.19M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $85.72M
Stockholders Equity Q1 2026 · Mar 31, 2026 $670.81M
Stockholders Equity Q1 2026 · Dec 31, 2025 $715.24M
Stockholders Equity Q1 2026 · Mar 31, 2025 $482.61M
Stockholders Equity Q1 2026 · Dec 31, 2024 $517.8M
Current Liabilities Q1 2026 · Mar 31, 2026 $85.16M
Current Liabilities Q1 2026 · Dec 31, 2025 $58.69M
Total Liabilities Q1 2026 · Mar 31, 2026 $93.14M
Total Liabilities Q1 2026 · Dec 31, 2025 $62.55M
Current Assets Q1 2026 · Mar 31, 2026 $763.95M
Current Assets Q1 2026 · Dec 31, 2025 $777.78M
Total Assets Q1 2026 · Mar 31, 2026 $763.95M
Total Assets Q1 2026 · Dec 31, 2025 $777.78M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.74
Sga Expense Q1 2026 · Mar 31, 2026 $15.23M
Sga Expense Q1 2026 · Mar 31, 2025 $11.94M
Net Income Q1 2026 · Mar 31, 2026 −$69.01M
Net Income Q1 2026 · Mar 31, 2025 −$44.77M
Operating Income Q1 2026 · Mar 31, 2026 −$45.64M
Operating Income Q1 2026 · Mar 31, 2025 −$53.57M